

Françoise Van Bambeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2419733/publications.pdf>

Version: 2024-02-01

222
papers

9,665
citations

29994

54
h-index

53109

85
g-index

226
all docs

226
docs citations

226
times ranked

10473
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Pseudomonas aeruginosa</i> : resistance and therapeutic options at the turn of the new millennium. <i>Clinical Microbiology and Infection</i> , 2007, 13, 560-578.	2.8	455
2	Antibiotic efflux pumps. <i>Biochemical Pharmacology</i> , 2000, 60, 457-470.	2.0	327
3	Quinolones in 2005: an update. <i>Clinical Microbiology and Infection</i> , 2005, 11, 256-280.	2.8	297
4	Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against <i>Staphylococcus aureus</i> in a Model of THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 841-851.	1.4	228
5	Intracellular <i>Staphylococcus aureus</i> persists upon antibiotic exposure. <i>Nature Communications</i> , 2020, 11, 2200.	5.8	197
6	Glycopeptide Antibiotics. <i>Drugs</i> , 2004, 64, 913-936.	4.9	181
7	Intracellular pharmacodynamics of antibiotics. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 615-634.	1.9	164
8	Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1055-1065.	1.3	162
9	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 649-658.	1.4	160
10	Antibiotic activity against small-colony variants of <i>Staphylococcus aureus</i> : review of in vitro, animal and clinical data. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1455-1464.	1.3	154
11	ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions. <i>Current Drug Targets</i> , 2011, 12, 600-620.	1.0	141
12	Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular <i>Staphylococcus aureus</i> in Mouse J774 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2283-2292.	1.4	140
13	The bacterial envelope as a target for novel anti-MRSA antibiotics. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 124-134.	4.0	129
14	Inhibitors of Bacterial Efflux Pumps as Adjuvants in Antibiotic Treatments and Diagnostic Tools for Detection of Resistance by Efflux. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006, 1, 157-175.	0.5	125
15	Gentamicin-induced apoptosis in LLC-PK1 cells: Involvement of lysosomes and mitochondria. <i>Toxicology and Applied Pharmacology</i> , 2005, 206, 321-333.	1.3	124
16	Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of β -Lactams, Azithromycin, Gentamicin, and Fluoroquinolones against <i>Listeria monocytogenes</i> at Clinically Relevant Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2095-2103.	1.4	116
17	A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against <i>Staphylococcus aureus</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2726-2737.	1.4	114
18	Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin. <i>Drug Safety</i> , 2009, 32, 359-378.	1.4	108

#	ARTICLE	IF	CITATIONS
19	Multidrug-Resistant <i>Streptococcus pneumoniae</i> Infections. <i>Drugs</i> , 2007, 67, 2355-2382.	4.9	104
20	Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by <i>Listeria monocytogenes</i> or <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1167-1173.	1.3	101
21	Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1177-1184.	1.3	100
22	Targeting the Type Three Secretion System in <i>Pseudomonas aeruginosa</i> . <i>Trends in Pharmacological Sciences</i> , 2016, 37, 734-749.	4.0	97
23	Glycopeptides in clinical development: pharmacological profile and clinical perspectives. <i>Current Opinion in Pharmacology</i> , 2004, 4, 471-478.	1.7	96
24	Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. <i>Free Radical Biology and Medicine</i> , 2011, 51, 1656-1665.	1.3	91
25	Increased Susceptibility of <i>Pseudomonas aeruginosa</i> to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of <i>oprM</i> and Increased Outer-Membrane Permeability. <i>Clinical Infectious Diseases</i> , 2012, 55, 534-542.	2.9	90
26	Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from <i>Staphylococcus aureus</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6385-6397.	1.4	88
27	Combined effect of pH and concentration on the activities of gentamicin and oxacillin against <i>Staphylococcus aureus</i> in pharmacodynamic models of extracellular and intracellular infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 246-253.	1.3	87
28	Macrolides: pharmacokinetics and pharmacodynamics. <i>International Journal of Antimicrobial Agents</i> , 2001, 18, 17-23.	1.1	83
29	Interactions of Macrolide Antibiotics (Erythromycin A, Roxithromycin, Erythromyclamine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Studies on Acellular and Cell Culture Models. <i>Toxicology and Applied Pharmacology</i> , 1999, 156, 129-140.	1.3	80
30	Reviving old antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2177-2181.	1.3	79
31	A combined phenotypic and genotypic method for the detection of Mex efflux pumps in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 378-386.	1.3	78
32	Interactions of ciprofloxacin with DPPC and DPPG: Fluorescence anisotropy, ATR-FTIR and ³¹ P NMR spectroscopies and conformational analysis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2008, 1778, 2535-2543.	1.4	78
33	Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2009, 1788, 1832-1840.	1.4	77
34	Optimizing β -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 677-688.	2.0	77
35	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. <i>Experimental Cell Research</i> , 2002, 281, 86-100.	1.2	76
36	Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Chemotherapy</i> , 2005, 49, 2429-2437.	1.4	76

#	ARTICLE	IF	CITATIONS
37	Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1067-1077.	1.3	75
38	2-Aminobenzothiazole derivatives: Search for new antifungal agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 357-364.	2.6	75
39	Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK 1 Cells Subjected to Electroporation. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1213-1221.	1.4	73
40	Cellular Pharmacokinetics of the Novel Biarylloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2540-2548.	1.4	73
41	In vivo development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 513-522.	1.1	72
42	Determining β -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1421-1428.	1.3	72
43	Vancomycin-Dependent <i>Enterococcus faecalis</i> Clinical Isolates and Revertant Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 41-47.	1.4	72
44	Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2853-2860.	1.4	66
45	Synthesis and Biological Evaluation of β -Mercapto- α -benzothiazole Derivatives with Potential Antimicrobial Activity. <i>Archiv Der Pharmazie</i> , 2009, 342, 605-613.	2.1	66
46	Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1047-1051.	1.4	64
47	Molecular models of human P-glycoprotein in two different catalytic states. <i>BMC Structural Biology</i> , 2009, 9, 3.	2.3	63
48	Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. <i>Future Microbiology</i> , 2015, 10, 1111-1123.	1.0	63
49	Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by <i>Listeria monocytogenes</i> and <i>Staphylococcus aureus</i> in J774 macrophages. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 511-517.	1.3	62
50	Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review. <i>Drugs</i> , 2015, 75, 2073-2095.	4.9	61
51	Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1035-1043.	1.3	59
52	Plectasin Shows Intracellular Activity against <i>Staphylococcus aureus</i> in Human THP-1 Monocytes and in a Mouse Peritonitis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4801-4808.	1.4	59
53	Cellular Pharmacodynamics of the Novel Biarylloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, Using <i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2549-2559.	1.4	58
54	Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 207-216.	1.3	55

#	ARTICLE	IF	CITATIONS
55	High-level resistance to meropenem in clinical isolates of <i>Pseudomonas aeruginosa</i> in the absence of carbapenemases: role of active efflux and porin alterations. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 740-743.	1.1	55
56	Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. <i>Current Opinion in Drug Discovery & Development</i> , 2006, 9, 218-30.	1.9	55
57	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a <i>Staphylococcus aureus</i> Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1434-1442.	1.4	54
58	Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2018, 24, 570-572.	2.8	54
59	Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. <i>European Journal of Pharmacology</i> , 1996, 314, 203-214.	1.7	53
60	Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized <i>Staphylococcus aureus</i> by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2748-2757.	1.4	53
61	Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against <i>Staphylococcus aureus</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> in Human THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3734-3743.	1.4	53
62	Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2673-2682.	1.4	52
63	Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against <i>Candida</i> spp. and <i>Aspergillus</i> spp. and reduced haemolytic and cytotoxic effects. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 236-244.	1.3	52
64	Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular <i>Staphylococcus aureus</i> , <i>Listeria monocytogenes</i> and <i>Legionella pneumophila</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 52-59.	1.1	52
65	New Amphiphilic Neamine Derivatives Active against Resistant <i>Pseudomonas aeruginosa</i> and Their Interactions with Lipopolysaccharides. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4420-4430.	1.4	52
66	Natural and hemi-synthetic pentacyclic triterpenes as antimicrobials and resistance modifying agents against <i>Staphylococcus aureus</i> : a review. <i>Phytochemistry Reviews</i> , 2018, 17, 1129-1163.	3.1	52
67	Activity of three β -lactams (ertapenem, meropenem and ampicillin) against intraphagocytic <i>Listeria monocytogenes</i> and <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 897-904.	1.3	50
68	Fluoroquinolones induce the expression of <i>patA</i> and <i>patB</i> , which encode ABC efflux pumps in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2076-2082.	1.3	50
69	Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards <i>Pseudomonas aeruginosa</i> PAO1 in a Model of THP-1 Human Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2310-2318.	1.4	49
70	Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in <i>Pseudomonas aeruginosa</i> isolated from patients suffering from cystic fibrosis. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 697-701.	1.1	47
71	Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. <i>European Journal of Pharmacology</i> , 1993, 247, 155-168.	2.7	44
72	Profile of a Novel Anionic Fluoroquinolone—Delafloxacin. <i>Clinical Infectious Diseases</i> , 2019, 68, S213-S222.	2.9	44

#	ARTICLE	IF	CITATIONS
73	Dynamics and Structural Changes Induced by ATP Binding in SAV1866, a Bacterial ABC Exporter. <i>Journal of Physical Chemistry B</i> , 2010, 114, 15948-15957.	1.2	43
74	Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> Isolated from Cystic Fibrosis Patients in Northern Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6735-6741.	1.4	43
75	Selection of quinolone resistance in <i>Streptococcus pneumoniae</i> exposed in vitro to subinhibitory drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 965-972.	1.3	42
76	Acquired resistance to macrolides in <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. <i>European Respiratory Journal</i> , 2017, 49, 1601847.	3.1	42
77	Restoration of Susceptibility of Methicillin-resistant <i>Staphylococcus aureus</i> to β -Lactam Antibiotics by Acidic pH. <i>Journal of Biological Chemistry</i> , 2008, 283, 12769-12776.	1.6	41
78	Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1) <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2289-2297.	1.4	41
79	Intracellular activity of the peptide antibiotic NZ2114: studies with <i>Staphylococcus aureus</i> and human THP-1 monocytes, and comparison with daptomycin and vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1720-1724.	1.3	41
80	The antifungal caspofungin increases fluoroquinolone activity against <i>Staphylococcus aureus</i> biofilms by inhibiting N-acetylglucosamine transferase. <i>Nature Communications</i> , 2016, 7, 13286.	5.8	41
81	Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular <i>Listeria monocytogenes</i> in a 24 h THP-1 human macrophage model. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1051-1052.	1.3	40
82	Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 761-767.	1.3	39
83	Role of <i>Staphylococcus aureus</i> and Staphyloxanthin in Phagocytosis and Intracellular Growth of <i>Staphylococcus aureus</i> in Human Macrophages and Endothelial Cells. <i>Journal of Infectious Diseases</i> , 2009, 200, 1367-1370.	1.9	39
84	Membrane destabilization induced by β -amyloid peptide 29-42: Importance of the amino-terminus. <i>Chemistry and Physics of Lipids</i> , 2002, 120, 57-74.	1.5	37
85	Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 267-283.	0.9	37
86	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a <i>Staphylococcus aureus</i> Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1443-1449.	1.4	37
87	Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of <i>Staphylococcus aureus</i> in Models of Extracellular (Broth) and Intracellular (THP-1 Monocytes) Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3700-3711.	1.4	36
88	Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. <i>European Journal of Pharmacology</i> , 1996, 314, 215-227.	1.7	35
89	Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts. <i>European Journal of Cell Biology</i> , 2001, 80, 466-478.	1.6	35
90	Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 249-56.	1.1	34

#	ARTICLE	IF	CITATIONS
91	Mechanisms of intrinsic resistance and acquired susceptibility of <i>Pseudomonas aeruginosa</i> isolated from cystic fibrosis patients to temocillin, a revived antibiotic. <i>Scientific Reports</i> , 2017, 7, 40208.	1.6	34
92	Synergy between Ursolic and Oleanolic Acids from <i>Vitellaria paradoxa</i> Leaf Extract and β -Lactams against Methicillin-Resistant <i>Staphylococcus aureus</i> : In Vitro and In Vivo Activity and Underlying Mechanisms. <i>Molecules</i> , 2017, 22, 2245.	1.7	34
93	<i>Artemisia</i> Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 960-964.	0.6	34
94	Glycopeptides and glycopeptide antibiotics in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. <i>Current Opinion in Investigational Drugs</i> , 2006, 7, 740-9.	2.3	34
95	Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes. <i>European Journal of Pharmacology</i> , 1995, 289, 321-333.	2.7	33
96	Biophysical studies and intracellular destabilization of pH-sensitive liposomes. <i>Lipids</i> , 2000, 35, 213-223.	0.7	33
97	Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in <i>Pseudomonas aeruginosa</i> by Distinct Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	33
98	Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1695-1700.	1.4	32
99	Role of Acidic pH in the Susceptibility of Intraphagocytic Methicillin-Resistant <i>Staphylococcus aureus</i> Strains to Meropenem and Cloxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1627-1632.	1.4	32
100	Activity of moxifloxacin against intracellular community-acquired methicillin-resistant <i>Staphylococcus aureus</i> : comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 596-607.	1.3	32
101	Activity of Fusidic Acid Against Extracellular and Intracellular <i>Staphylococcus aureus</i> : Influence of pH and Comparison With Linezolid and Clindamycin. <i>Clinical Infectious Diseases</i> , 2011, 52, S493-S503.	2.9	31
102	Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of <i>Staphylococcus aureus</i> isolates from a patient with persistent bacteraemia and endocarditis. <i>Clinical Microbiology and Infection</i> , 2008, 14, 766-777.	2.8	30
103	Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic Tj ETQq1 1 0.784314 mg BT / Overclock 10		
104	Cellular pharmacokinetics and intracellular activity against <i>Listeria monocytogenes</i> and <i>Staphylococcus aureus</i> of chemically modified and nanoencapsulated gentamicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2158-2164.	1.3	30
105	Mechanisms of Action. , 2017, , 1162-1180.e1.		30
106	Impairment of Growth of <i>Listeria monocytogenes</i> in THP-1 Macrophages by Granulocyte Macrophage Colony-Stimulating Factor: Release of Tumor Necrosis Factor- α and Nitric Oxide. <i>Journal of Infectious Diseases</i> , 2004, 189, 2101-2109.	1.9	29
107	Sequencing of the <i>ddl</i> gene and modeling of the mutated D-alanine:D-alanine ligase in glycopeptide-dependent strains of <i>Enterococcus faecium</i> . <i>Protein Science</i> , 2001, 10, 836-844.	3.1	28
108	Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. <i>Proteins: Structure, Function and Bioinformatics</i> , 2006, 63, 466-478.	1.5	28

#	ARTICLE	IF	CITATIONS
109	Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones. <i>Annals of Medicine</i> , 2014, 46, 512-529.	1.5	28
110	DD-Ligases as a Potential Target for Antibiotics: Past, Present and Future. <i>Current Medicinal Chemistry</i> , 2009, 16, 2566-2580.	1.2	27
111	Avibactam confers susceptibility to a large proportion of ceftazidime-resistant <i>Pseudomonas aeruginosa</i> isolates recovered from cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1596-1598.	1.3	27
112	Cooperation between Prokaryotic (Lde) and Eukaryotic (MRP) Efflux Transporters in J774 Macrophages Infected with <i>Listeria monocytogenes</i> : Studies with Ciprofloxacin and Moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3040-3046.	1.4	26
113	Restoration of Susceptibility of Intracellular Methicillin-Resistant <i>Staphylococcus aureus</i> to β -Lactams: Comparison of Strains, Cells, and Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2797-2805.	1.4	26
114	Identification of the Efflux Transporter of the Fluoroquinolone Antibiotic Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2410-2416.	1.4	26
115	Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from <i>Staphylococcus aureus</i> . <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 1876-1885.	1.4	26
116	Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs <i>Pseudomonas aeruginosa</i> Pathogenicity and Inflammasome Activation. <i>Journal of Infectious Diseases</i> , 2016, 214, 1105-1116.	1.9	26
117	Cellular Accumulation and Activity of Quinolones in Ciprofloxacin-Resistant J774 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1689-1695.	1.4	24
118	Passive diffusion of polymeric surfactants across lipid bilayers. <i>Journal of Controlled Release</i> , 2007, 120, 79-87.	4.8	24
119	Intra- and extracellular activity of linezolid against <i>Staphylococcus aureus</i> in vivo and in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 962-973.	1.3	24
120	Great phenotypic and genetic variation among successive chronic <i>Pseudomonas aeruginosa</i> from a cystic fibrosis patient. <i>PLoS ONE</i> , 2018, 13, e0204167.	1.1	24
121	Host Cell Oxidative Stress Induces Dormant <i>Staphylococcus aureus</i> Persists. <i>Microbiology Spectrum</i> , 2022, 10, e0231321.	1.2	24
122	Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial <i>Candida albicans</i> / <i>Staphylococcus aureus</i> biofilms on intraperitoneally implanted foreign bodies. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2806-2814.	1.3	23
123	Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. <i>Chemistry and Physics of Lipids</i> , 2005, 133, 1-15.	1.5	21
124	Intra- and Extracellular Activities of Dicloxacillin against <i>Staphylococcus aureus</i> In Vivo and In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2391-2400.	1.4	21
125	Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin. <i>Clinical Infectious Diseases</i> , 2012, 54, S229-S232.	2.9	21
126	Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Cultured Human HL-60 Promyelocytes and THP-1 Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21

#	ARTICLE	IF	CITATIONS
127	Experimental and Conformational Analyses of Interactions between Butenafine and Lipids. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3347-3354.	1.4	20
128	Pharmacological Characterization of 7-(4-(Piperazin-1-yl)) Ciprofloxacin Derivatives: Antibacterial Activity, Cellular Accumulation, Susceptibility to Efflux Transporters, and Intracellular Activity. <i>Pharmaceutical Research</i> , 2014, 31, 1290-1301.	1.7	20
129	Increase of efflux-mediated resistance in <i>Pseudomonas aeruginosa</i> during antibiotic treatment in patients suffering from nosocomial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 77-83.	1.1	20
130	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 324-338.	2.6	20
131	Activity of Antibiotics against <i>Staphylococcus aureus</i> in an <i>In Vitro</i> Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	20
132	Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers. <i>Antibiotics</i> , 2021, 10, 530.	1.5	20
133	Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112444.	2.6	20
134	Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. <i>FEBS Letters</i> , 1996, 394, 307-310.	1.3	19
135	Accumulation and Oriented Transport of Ampicillin in Caco-2 Cells from Its Pivaloyloxymethylester Prodrug, Pivampicillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1279-1288.	1.4	19
136	Intra- and Extracellular Activities of Dicloxacillin and Linezolid against a Clinical <i>Staphylococcus aureus</i> Strain with a Small-Colony-Variant Phenotype in an <i>In Vitro</i> Model of THP-1 Macrophages and an <i>In Vivo</i> Mouse Peritonitis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1443-1452.	1.4	19
137	Study of Macrophage Functions in Murine J774 Cells and Human Activated THP-1 Cells Exposed to Oritavancin, a Lipoglycopeptide with High Cellular Accumulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2059-2066.	1.4	19
138	Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against <i>Staphylococcal</i> Biofilms in <i>In Vitro</i> Static and Dynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	19
139	Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 518-521.	1.3	18
140	Isolation and 2D DIGE proteomic analysis of intracellular and extracellular forms of <i>Listeria monocytogenes</i> . <i>Proteomics</i> , 2009, 9, 5484-5496.	1.3	18
141	Antibiotic Activity against Naive and Induced <i>Streptococcus pneumoniae</i> Biofilms in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1348-1358.	1.4	18
142	Activity of Antibiotics against <i>Pseudomonas aeruginosa</i> in an <i>In Vitro</i> Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	18
143	Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 101-110.	1.3	17
144	Activities of Antibiotic Combinations against Resistant Strains of <i>Pseudomonas aeruginosa</i> in a Model of Infected THP-1 Monocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 258-268.	1.4	17

#	ARTICLE	IF	CITATIONS
145	The role of solithromycin in the management of bacterial community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 311-324.	2.0	17
146	Increased Azithromycin Susceptibility of Multidrug-Resistant Gram-Negative Bacteria on RPMI-1640 Agar Assessed by Disk Diffusion Testing. <i>Antibiotics</i> , 2020, 9, 218.	1.5	17
147	Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2236-2238.	1.4	16
148	Role of MexAB-OprM in intrinsic resistance of <i>Pseudomonas aeruginosa</i> to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 771-775.	1.3	16
149	Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant <i>Staphylococcus aureus</i> : comparison with vancomycin, linezolid and daptomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 648-658.	1.3	16
150	Correlation between cytotoxicity induced by <i>Pseudomonas aeruginosa</i> clinical isolates from acute infections and IL-1 β secretion in a model of human THP-1 monocytes. <i>Pathogens and Disease</i> , 2015, 73, ftv049.	0.8	16
151	Cellular Pharmacokinetics and Intracellular Activity of the Novel Peptide Deformylase Inhibitor GSK1322322 against <i>Staphylococcus aureus</i> Laboratory and Clinical Strains with Various Resistance Phenotypes: Studies with Human THP-1 Monocytes and J774 Murine Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5747-5760.	1.4	16
152	Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 702-708.	1.1	16
153	Antibiotic Resistance, Biofilm Formation, and Intracellular Survival As Possible Determinants of Persistent or Recurrent Infections by <i>Staphylococcus aureus</i> in a Vietnamese Tertiary Hospital: Focus on Bacterial Response to Moxifloxacin. <i>Microbial Drug Resistance</i> , 2020, 26, 537-544.	0.9	16
154	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1630-1635.	2.8	16
155	Activity of quinupristin/dalfopristin against extracellular and intracellular <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1228-1236.	1.3	15
156	Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant <i>Staphylococcus aureus</i> are hypersusceptible to β -lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2873-2881.	1.3	15
157	Aminoglycoside antibiotics prevent the formation of non-bilayer structures in negatively-charged membranes. Comparative studies using fusogenic (bis(1 β -diethylaminoethylether)hexestrol) and aggregating (spermine) agents. <i>Chemistry and Physics of Lipids</i> , 1996, 79, 123-135.	1.5	14
158	Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against <i>Staphylococcus aureus</i> Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	14
159	Influence of pH on the activity of finafloxacin against extracellular and intracellular <i>Burkholderia thailandensis</i> , <i>Yersinia pseudotuberculosis</i> and <i>Francisella philomiragia</i> and on its cellular pharmacokinetics in THP-1 monocytes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1254.e1-1254.e8.	2.8	14
160	Piracetam inhibits the lipid-destabilising effect of the amyloid peptide A β C-terminal fragment. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1609, 28-38.	1.4	13
161	Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of <i>Staphylococcus aureus</i> and Their Wild-Type Parental Strain in Human THP-1 Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6166-6174.	1.4	13
162	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. <i>Clinical Biochemistry</i> , 2015, 48, 542-545.	0.8	12

#	ARTICLE	IF	CITATIONS
163	Modulating antibiotic activity towards respiratory bacterial pathogens by co-mediations: a multi-target approach. <i>Drug Discovery Today</i> , 2016, 21, 1114-1129.	3.2	12
164	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. <i>Methods in Molecular Biology</i> , 2016, 1333, 147-157.	0.4	12
165	Characterization of Abcc4 Gene Amplification in Stepwise-Selected Mouse J774 Macrophages Resistant to the Topoisomerase II Inhibitor Ciprofloxacin. <i>PLoS ONE</i> , 2011, 6, e28368.	1.1	12
166	Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 192-197.	1.4	11
167	The Persister Character of Clinical Isolates of <i>Staphylococcus aureus</i> Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin. <i>Frontiers in Microbiology</i> , 2020, 11, 587364.	1.5	11
168	Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive <i>Streptococcus pneumoniae</i> Isolates (1995-2014). <i>PLoS ONE</i> , 2016, 11, e0154816.	1.1	11
169	Structure-Based Design of Benzoxazoles as new Inhibitors for D-Alanyl - D-Alanine Ligase. <i>QSAR and Combinatorial Science</i> , 2009, 28, 1394-1404.	1.5	10
170	Penicillin-binding Proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in Beta-lactam sensitivity of <i>Listeria monocytogenes</i> . <i>Gut Pathogens</i> , 2009, 1, 23.	1.6	10
171	Characterisation of a collection of <i>Streptococcus pneumoniae</i> isolates from patients suffering from acute exacerbations of chronic bronchitis: In vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 209-217.	1.1	10
172	Synergistic activity between an antimicrobial polyacrylamide and daptomycin versus <i>Staphylococcus aureus</i> biofilm. <i>Pathogens and Disease</i> , 2016, 74, ftw042.	0.8	10
173	Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. <i>Toxicology</i> , 2011, 290, 178-186.	2.0	9
174	Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models. <i>Frontiers in Microbiology</i> , 2017, 8, 2585.	1.5	9
175	Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Benin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 54.	1.7	9
176	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2650-2656.	1.3	9
177	The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	9
178	Role of Efflux in Antibiotic Resistance of <i>Achromobacter xylosoxidans</i> and <i>Achromobacter insuavis</i> Isolates From Patients With Cystic Fibrosis. <i>Frontiers in Microbiology</i> , 2022, 13, 762307.	1.5	9
179	Intracellular accumulation and activity of ampicillin used as freedrug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against <i>Listeria monocytogenes</i> in J774 macrophages. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 610-615.	1.3	8
180	Antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 208-216.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Preliminary evidences of the direct and indirect antimicrobial activity of 12 plants used in traditional medicine in Africa. <i>Phytochemistry Reviews</i> , 2015, 14, 975-991.	3.1	8
182	Synergistic Effects of Pulsed Lavage and Antimicrobial Therapy Against <i>Staphylococcus aureus</i> Biofilms in an in-vitro Model. <i>Frontiers in Medicine</i> , 2020, 7, 527.	1.2	8
183	Analysis of the Membrane Proteome of Ciprofloxacin-Resistant Macrophages by Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC). <i>PLoS ONE</i> , 2013, 8, e58285.	1.1	8
184	Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105825.	1.1	7
185	<i>In Vitro</i> Study of the Synergistic Effect of an Enzyme Cocktail and Antibiotics against Biofilms in a Prosthetic Joint Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
186	Intracellular Activity of Antibiotics against <i>Coxiella burnetii</i> in a Model of Activated Human THP-1 Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0106121.	1.4	7
187	Uropathogenic <i>Escherichia coli</i> Shows Antibiotic Tolerance and Growth Heterogeneity in an <i>In Vitro</i> Model of Intracellular Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0146821.	1.4	7
188	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. <i>Experimental Cell Research</i> , 2002, 281, 86-86.	1.2	6
189	The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of <i>Pseudomonas aeruginosa</i> Exposed to Fluoroquinolones. <i>Frontiers in Microbiology</i> , 2018, 9, 1455.	1.5	6
190	Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of <i>Staphylococcus aureus</i> in models of cultured phagocytic cells. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105848.	1.1	6
191	First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing <i>Acinetobacter baumannii</i> using whole genome sequencing, isolated in a clinical setting in Benin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 5.	1.7	6
192	Antimicrobial potentials of essential oils extracted from West African aromatic plants on common skin infections. <i>Scientific African</i> , 2021, 11, e00706.	0.7	6
193	Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 660-665.	1.1	5
194	Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw587.	1.3	5
195	<i>In vitro</i> polymicrobial inter-kingdom three-species biofilm model: influence of hyphae on biofilm formation and bacterial physiology. <i>Biofouling</i> , 2021, 37, 481-493.	0.8	5
196	Hydrolytic Enzymes as Potentiators of Antimicrobials against an Inter-Kingdom Biofilm Model. <i>Microbiology Spectrum</i> , 2022, 10, e0258921.	1.2	5
197	Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of <i>Staphylococcus aureus</i> Differing by Their Resistant or Persister Character to Fluoroquinolones. <i>Frontiers in Microbiology</i> , 2021, 12, 785573.	1.5	5
198	Antibiotic Usage in Patients Having Undergone Caesarean Section: A Three-Level Study in Benin. <i>Antibiotics</i> , 2022, 11, 617.	1.5	5

#	ARTICLE	IF	CITATIONS
199	The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114496.	2.6	5
200	Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of <i>Streptococcus pneumoniae</i> naive and induced biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1713-26.	1.3	4
201	Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1630-1638.	1.3	4
202	Modeling of <i>Enterococcus faecalis</i> D-alanine:D-alanine ligase: structure-based study of the active site in the wild-type enzyme and in glycopeptide-dependent mutants. <i>Journal of Molecular Microbiology and Biotechnology</i> , 2000, 2, 321-30.	1.0	4
203	Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations against <i>In Vitro</i> Polymicrobial Interkingdom Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0214921.	1.4	4
204	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. <i>Antibiotics</i> , 2022, 11, 898.	1.5	4
205	<i>Pseudomonas aeruginosa</i> : Résistance et options thérapeutiques à l'ère du deuxième millénaire. <i>Antibiotiques</i> , 2007, 9, 189-198.	0.1	3
206	Efflux of novel quinolones in contemporary <i>Streptococcus pneumoniae</i> isolates from community-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 948-951.	1.3	3
207	Macrolides and Ketolides. , 2014, , 257-278.		3
208	Editorial Commentary: Colistin and a New Paradigm in Drug Development. <i>Clinical Infectious Diseases</i> , 2016, 62, 559-560.	2.9	3
209	Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 661-667.	1.1	3
210	Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 330-336.	1.1	3
211	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1459-1461.	1.3	2
212	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. <i>Methods in Molecular Biology</i> , 2021, 2357, 239-251.	0.4	2
213	Healthcare Professionals' Knowledge and Beliefs on Antibiotic Prophylaxis in Cesarean Section: A Mixed-Methods Study in Benin. <i>Antibiotics</i> , 2022, 11, 872.	1.5	2
214	Inhibition of TNF- α production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by <i>Listeria monocytogenes</i> and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 288-289.	1.3	1
215	Comparison of three differential media for the presumptive identification of yeasts. <i>Clinical Microbiology and Infection</i> , 2005, 11, 513-515.	2.8	1
216	RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (<i>Staphylococcus aureus</i>) and Gram-Negative (<i>Pseudomonas aeruginosa</i>) Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4750-4758.	1.4	1

#	ARTICLE	IF	CITATIONS
217	4CPS-031 Audit of antibiotic prophylaxis practice in visceral surgery in an African country. , 2020, , .		1
218	Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Pharmaceutics</i> , 2021, 13, 456.	2.0	1
219	Dangerous Slimes: How Bacterial Biofilms Make You Sick and How to Combat Them. <i>Frontiers for Young Minds</i> , 0, 8, .	0.8	1
220	Editorial [Hot Topic: ABC Transporters: Role in Modulation of Drug Pharmacokinetics and in Physiopathology and Therapeutic Perspectives (Guest Editor: Françoise Van Bambeke)]. <i>Current Drug Targets</i> , 2011, 12, 598-599.	1.0	0
221	Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1414-1415.	1.3	0
222	Mechanisms of action. , 2010, , 1288-1307.		0